Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2011 | Varian

Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2011

PALO ALTO, Calif., July 27, 2011 /ja/PRNewswire/ja/ -- Varian Medical Systems (NYSE: VAR) today is reporting net earnings from continuing operations of $0.83 per diluted share in the third quarter of fiscal year 2011, up 12 percent from $0.74 in the year-ago quarter.  Revenues for the quarter were $649 million, up 12 percent from the prior-year period and up 9 percent on a constant currency basis.  Order backlog at the end of the third quarter rose 10 percent from the prior-year quarter to $2.3 billion.

"Continued healthy demand for newer products contributed to solid growth in net orders and revenues during the third quarter in both our Oncology Systems and X-Ray Products business segments," said Tim Guertin, president and CEO of Varian Medical Systems.  "A variety of factors, including product retrofits in our Oncology business as well as challenging conditions in our Other segment, contributed to lower than normal gross margin for the quarter. Year-to-date, gross margins are up by half a percent."

At the end of the quarter, the company had $568 million in cash and cash equivalents and $18 million of debt.  During the third quarter, the company retired an additional 631,000 shares to complete the previously announced accelerated share repurchase program.  Fully diluted shares outstanding for the quarter were 119.1 million, down 5.4 million from the year-ago quarter.  Days sales outstanding for the quarter was 81, an increase of 1 day from the year-ago period.  

Oncology Systems

Third quarter revenues from Oncology Systems' products and services for radiotherapy, radiosurgery, and brachytherapy totaled $513 million, up 12 percent from the same period last fiscal year.  Third quarter net orders totaled $553 million, up 9 percent versus the year-ago period.  Net orders rose 18 percent in international markets and were even with the year-ago period in North America.

"Continued strong demand for our TrueBeam platform and service contracts led to the order and revenue growth during the quarter," Guertin said. "Our TrueBeam platform for radiotherapy and radiosurgery represented more than 40 percent of all machines ordered during the quarter.  This platform enabled us to gain market share in North America while driving growth in international markets with major wins in Scotland, Norway, and Saudi Arabia."

X-Ray Products

Third quarter revenues from x-ray tubes and flat panel image detectors for filmless imaging were $121 million, up 18 percent from the year-ago quarter.  Compared to the same period in fiscal year 2010, X-Ray Products' third quarter net orders rose 17 percent to $121 million.    

"Demand for our full range of products remained strong in the third quarter," said Guertin.  "X-ray tubes for CT scanners, mammography, and service replacement tubes grew at a double-digit pace."  The overall growth of X-Ray Products segment continued to be led by its radiographic imaging panels that were introduced last year.

Other

The company's Other category, which is comprised of the Security and Inspection Products (SIP) business, the Varian Particle Therapy business, and the Ginzton Technology Center, recorded third quarter revenues of $16 million, down 18 percent from the year-ago period.  Net orders in the company's Other category were $17 million, down 12 percent from the year-ago quarter.

Outlook

"We continue to estimate that revenues for fiscal year 2011 could grow 10 to 11 percent over the fiscal 2010 total," said Guertin. "We now believe that net earnings per diluted share from continuing operations for the year could grow by about 16 percent to be in the range of $3.42 to $3.45."  

Investor Conference Call

Varian Medical Systems is scheduled to conduct its third quarter fiscal year 2011 conference call at 2 p.m. PT today.  To hear a live webcast or replay of the call, visit the investor relations page on the company's web site at www.varian.com/ja/ja/ja/investor where it will be archived for a year.  To access the call via telephone, dial 1-866-383-8108 from inside the U.S. or 1-617-597-5343 from outside the U.S. and enter confirmation code 51675560.  The replay can be accessed by dialing 1 888 286-8010 from inside the U.S. or 1-617-801-6888 from outside the U.S. and entering confirmation code 94903998. The telephone replay will be available through 5 p.m. PT, Friday, July 29, 2011.

For automatic "e-mail alerts" regarding Varian news, events, and new investor materials on the website, investors can subscribe on the company website:
http:/ja//ja/varian.investorroom.com/ja/index.php?s=58. For additional information, contact investor relations at 1 650 424-5834.

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,700 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http:/ja//ja/www.varian.com.

Forward-Looking Statements

Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry outlook, including growth drivers; the company's future orders, revenues, backlog, or earnings growth; future financial results; market acceptance of or transition to new products or technology such as TrueBeam and radiographic flat panel detectors, image-guided radiation therapy, stereotactic radiosurgery, filmless X-rays, proton therapy, and security and inspection, and any statements using the terms "could," "believe," "outlook," or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include the effect of economic conditions, including the strength of any recovery from the global recession; the impact of recently enacted federal health care legislation and any further health care reforms (including changes to Medicare and Medicaid), and/ja/or changes in third-party reimbursement levels; currency exchange rates and tax rates; demand for the company's products; the company's ability to develop, commercialize, and deploy new products such as the TrueBeam platform; the company's ability to meet Food and Drug Administration (FDA) and other regulatory requirements for product clearances or to comply with FDA and other regulatory regulations or procedures; changes in the regulatory environment, including with respect to FDA requirements; challenges in reducing or eliminating ongoing commitments retained from our discontinued research instruments business; the effect of adverse publicity; the company's reliance on sole or limited-source suppliers; the impact of reduced or limited demand by purchasers of certain X-ray products, including those located in Japan; the company's ability to maintain or increase margins; the impact of competitive products and pricing; the potential loss of key distributors or key personnel; challenges to public tender awards and the loss of such awards or other orders; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.

A summary of earnings and other financial information follows.


 
 

 

Varian Medical Systems, Inc. and Subsidiaries
Condensed Consolidated Statements of Earnings
(Unaudited)
 

 

 

(Dollars and shares in millions, except per share amounts)


 

Q3 QTR

2011


 

Q3 QTR

2010


 

Q3YTD

2011


 

Q3YTD

2010


 
 

 

Net orders

$

691.3


 

629.3


 

1,965.6


 

1,718.1


 
 

 

 Oncology Systems


 

553.2


 

506.6


 

1,532.3


 

1,419.3


 
 

 

 X-Ray Products


 

120.9


 

103.2


 

356.5


 

306.9


 
 

 

 Security & Inspection Products


 

15.7


 

18.0


 

74.1


 

51.8


 
 

 

 Varian Particle Therapy  (1)


 

1.1


 

0.4


 

2.3


 

(61.0)


 
 

 

  Ginzton Technology Center


 

0.4


 

1.1


 

0.4


 

1.1


 
 

 

Order backlog

$

2,280.5


 

2,068.0


 

2,280.5


 

2,068.0


 
 

 

Revenues

$

649.4


 

578.0


 

1,877.7


 

1,704.5


 
 

 

 Oncology Systems


 

512.5


 

455.9


 

1,472.8


 

1,350.5


 
 

 

 X-Ray Products


 

120.8


 

102.3


 

350.2


 

295.9


 
 

 

 Other


 

16.1


 

19.8


 

54.7


 

58.1


 
 

 

Cost of revenues

$

369.6


 

323.6


 

1,042.1


 

955.1


 
 

 

Gross margin


 

279.8


 

254.4


 

835.6


 

749.4


 
 

 

 As a percent of revenues


 

43.1%


 

44.0%


 

44.5%


 

44.0%


 
 

 

Operating expenses


 

 

 

 

 

 

 

 

 
 

 

 Research and development  


 

44.4


 

38.9


 

126.8


 

116.2


 
 

 

 Selling, general and administrative  


 

94.9


 

84.7


 

280.1


 

247.8


 
 

 

Operating earnings


 

140.5


 

130.8


 

428.7


 

385.4


 
 

 

 As a percent of revenues


 

21.6%


 

22.6%


 

22.8%


 

22.6%


 
 


 

Interest income/ja/(expense), net


 

0.1


 

(0.9)


 

0.2


 

(1.5)


 
 

 

Earnings from continuing operations before taxes


 

140.6


 

129.9


 

428.9


 

383.9


 
 

 

Taxes on earnings


 

42.0


 

38.0


 

130.7


 

122.1


 
 

 

Earnings from continuing operations  


 

98.6


 

91.9


 

298.2


 

261.8


 
 

 

 As a percent of revenues


 

15.2%


 

15.9%


 

15.9%


 

15.4%


 
 

 

Loss  from discontinued operations – net of  taxes  (2)


 

-


 

(6.4)


 

-


 

(6.4)


 
 

 

Net earnings

$

98.6


 

85.5


 

298.2


 

255.4


 
 

 

 

 

 

 

 

 

 

 

 

 
 

 

Net earnings (loss) per share – basic:


 

 

 

 

 

 

 

 

 
 

 

  Continuing operations

$

0.84


 

0.75


 

2.54


 

2.13


 
 

 

  Discontinued operations  (2)


 

-


 

(0.05)


 

-


 

(0.05)


 
 

 

  Net earnings per share

$

0.84


 

0.70


 

2.54


 

2.08


 
 

 

Net earnings (loss)  per share – diluted:


 

 

 

 

 

 

 

 

 
 

 

  Continuing operations

$

0.83


 

0.74


 

2.49


 

2.10


 
 

 

  Discontinued operations  (2)


 

-


 

(0.05)


 

-


 

(0.05)


 
 

 

  Net earnings per share

$

0.83


 

0.69


 

2.49


 

2.05


 
 

 

 

 

 

 

 

 

 

 

 

 
 

 

Shares used in the calculation of net earnings per share:    


 

 

 

 

 

 

 

 

 
 

 

Average shares outstanding - basic


 

116.9


 

122.1


 

117.6


 

122.9


 
 

 

Average shares outstanding - diluted


 

119.1


 

124.5


 

119.8


 

124.5


 
 

 

 

 

 

 

 

 

 

 

 

 
 

(1) Net orders for Q3 2010 YTD include $62 million for the cancellation of the Skandion Kliniken proton therapy system order.

(2) The operating results of ACCEL research instruments are classified as discontinued operations for all periods presented.
 

 
                     

 

 
 

Varian Medical Systems, Inc. and Subsidiaries

 

Condensed Consolidated Balance Sheets

 

 

 

 

 

 
 

(In thousands)


 

July 1,


 

October 1,

 

2011

2010 (1)

 

(Unaudited)


 
 

Assets


 

 

 

 
 

Current assets


 

 

 

 
 

   Cash and cash equivalents

$

567,922

$

520,221

 

   Accounts receivable, net


 

581,862


 

591,677

 

   Inventories                                        


 

438,483


 

363,933

 

   Deferred tax assets and other                                


 

249,185


 

205,513

 

Total current assets                                        


 

1,837,452


 

1,681,344

 

 

 

 

 

 
 

Property, plant and equipment                                            


 

598,550


 

562,763

 

   Accumulated depreciation and amortization                    


 

(315,365)


 

(294,836)

 

Property, plant and equipment, net                          


 

283,185


 

267,927

 

 

 

 

 

 
 

Goodwill


 

216,063


 

208,451

 

Other assets                                                    


 

176,579


 

166,230

 

Total assets                                              

$

2,513,279

$

2,323,952

 

 

 

 

 

 
 

Liabilities and Stockholders' Equity


 

 

 

 
 

Current liabilities                                                        


 

 

 

 
 

   Accounts payable                                              

$

119,836

$

119,018

 

   Accrued expenses                                              


 

300,391


 

287,851

 

   Deferred revenues                                              


 

131,012


 

141,916

 

   Advance payments from customers                              


 

316,948


 

275,998

 

   Product warranty                                                        


 

51,969


 

53,233

 

   Short-term borrowings


 

-


 

20,000

 

   Current maturities of long-term debt                              


 

11,689


 

5,525

 

Total current liabilities                                  


 

931,845


 

903,541

 

Other long-term liabilities


 

121,137


 

127,175

 

Long-term debt                                                            


 

6,250


 

17,869

 

Total liabilities                                          


 

1,059,232


 

1,048,585

 

 

 

 

 

 
 

Stockholders' Equity


 

 

 

 
 

Common stock


 

117,075


 

118,007

 

Capital in excess of par value


 

596,400


 

508,366

 

Retained earnings and accumulated other comprehensive loss  


 

740,572


 

648,994

 

Total stockholders' equity                                  


 

1,454,047


 

1,275,367

 

Total liabilities and stockholders' equity              

$

2,513,279

$

2,323,952

 

 
 

(1)  The condensed consolidated balance sheet as of October 1, 2010 was derived from audited financial statements as of that date.
 

 
         

 

FOR INFORMATION CONTACT:
Elisha Finney (650) 424-6803
elisha.finney@varian.com

Spencer Sias (650) 424-5782
spencer.sias@varian.com

SOURCE Varian Medical Systems